Insmed Appoints Two New Directors to Its Board
Insmed Inc INSM
News
Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan
Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026
Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026
Insmed Announces CFO Transition
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027
Insmed Expands Community Impact During Fifth Annual Global Day of Good
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
Insmed to Present at September 2026 Investor Conferences
BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
Stocks to Watch: Micron, MillerKnoll, HireQuest, Insmed
Walmart was too late for a Nasdaq-100 spot - but these 6 stocks made the cut
These 15 stocks are still showing momentum - and a market-beating edge
United States